Good news! Cancer is history! There are even similarities to Covid-19 vaccines!
"A recent study showed that personalized cancer vaccines designed to fight melanoma, the deadliest form of skin cancer, maintain their effects on the immune system years after inoculation — another step in efforts to harness the immune system as an ally in the fight against cancers of all kinds. ...
A personalized cancer vaccine ... because the key here is that the personalization allows us to target new antigens that are very specific to tumors. ... really only seen in that individual patient’s tumor ... Each individual vaccine is different, it’s not an off-the-shelf therapeutic. ...
What is interesting is that both companies that developed now-FDA-approved RNA vaccines against SARS-CoV-2, Moderna and BioNTech, are also pioneers in the neoantigen vaccine field. Ugur Sahin, the founder of BioNTech, for example, published along with us in Nature 2017 on a similar study on melanoma patients using an RNA vaccine. BioNTech, partnering with Genentech, is running randomized, personalized vaccine studies in cancer patients already."
A personalized cancer vaccine ... because the key here is that the personalization allows us to target new antigens that are very specific to tumors. ... really only seen in that individual patient’s tumor ... Each individual vaccine is different, it’s not an off-the-shelf therapeutic. ...
What is interesting is that both companies that developed now-FDA-approved RNA vaccines against SARS-CoV-2, Moderna and BioNTech, are also pioneers in the neoantigen vaccine field. Ugur Sahin, the founder of BioNTech, for example, published along with us in Nature 2017 on a similar study on melanoma patients using an RNA vaccine. BioNTech, partnering with Genentech, is running randomized, personalized vaccine studies in cancer patients already."
"... We observed long-term persistence of neoantigen-specific T cell responses following vaccination, with ex vivo detection of neoantigen-specific T cells exhibiting a memory phenotype. We also found diversification of neoantigen-specific T cell clones over time, with emergence of multiple T cell receptor clonotypes exhibiting distinct functional avidities. Furthermore, we detected evidence of tumor infiltration by neoantigen-specific T cell clones after vaccination and epitope spreading, suggesting on-target vaccine-induced tumor cell killing. Personal neoantigen peptide vaccines thus induce T cell responses that persist over years and broaden the spectrum of tumor-specific cytotoxicity in patients with melanoma."
This appears to be the related research article:
No comments:
Post a Comment